Oral Cavity Cancer Clinical Trial
Official title:
A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804
The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.
This is a single-center, randomized, double-blinded, biomarker driven, preoperative window of opportunity study with a pharmacodynamic primary endpoint. Patients with resectable, histologically confirmed OCC for whom surgical treatment is planned as definitive management, will be randomized 2:1 to receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days or to Matching Placebo for 7-11 days depending on surgery schedule. The target is a total of 8 days of treatment but with a minimum of 7 and a maximum of 11 dosing days. All patients will receive surgery as per standard of care without delay. Biomarkers from the surgical specimen and baseline tumor biopsy or consent to provide a tumor block from existing primary diagnostic tumor biopsy completed within 90 days will be evaluated for primary and secondary pharmacodynamic endpoints. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01695122 -
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05793151 -
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
|
N/A | |
Recruiting |
NCT01958762 -
Screening for Cancers in the Oral CAvity
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05757817 -
Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae
|
N/A | |
Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
Recruiting |
NCT04809324 -
Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Terminated |
NCT03555721 -
CytID Analysis of Oral Lesions
|
||
Recruiting |
NCT05375266 -
Immune Biomarker Study for Head and Neck Cancer
|
||
Active, not recruiting |
NCT03082534 -
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03096808 -
Adaptive Radiotherapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00359645 -
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
|
Phase 3 | |
Completed |
NCT02412241 -
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
|
N/A | |
Terminated |
NCT00934739 -
A Study of High-Risk Oral Cavity Cancer
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06407570 -
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
|
||
Recruiting |
NCT05337631 -
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
|
||
Recruiting |
NCT05927220 -
WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA
|
||
Recruiting |
NCT05369234 -
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
|
Phase 3 | |
Completed |
NCT05056064 -
Efficacy of Swallowing Function After Early Postoperative Oral Exercise Among Patient With Oral Cavity Cancer Underwent Flap Reconstruction
|
N/A |